Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADI-R403 is a research and discovery program developed by Bio-Modeling Systems (BMSystems) that focuses on the biological mechanisms underlying hypercholesterolemia. Developed using the company's proprietary CADI™ (Computer Assisted Deductive Integration) platform, the program employs a non-mathematical, deductive integration approach to model the complex, non-linear pathways of cholesterol metabolism. By identifying the causal mechanisms of the disease rather than just its symptoms, CADI-R403 aims to discover novel therapeutic targets and diagnostic biomarkers for metabolic and cardiovascular disorders. The program is part of BMSystems' broader metabolism portfolio and has reached the stage where a validated mechanism-based model has been produced to support further drug development or therapeutic protocol design.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CADI-R403.